Antiviral Treatment for Influenza

First-Line Recommendation

Oseltamivir (Tamiflu) is the antiviral of choice for influenza in both adults and children ≥1 year, dosed at 75 mg orally twice daily for 5 days in adults and weight-based dosing in children, initiated as soon as possible within 48 hours of symptom onset. 1, 2

Who Should Receive Immediate Treatment

Mandatory Treatment Groups (Start Immediately, Regardless of Timing)

All children <2 years of age with suspected or confirmed influenza require immediate oseltamivir treatment due to exceptionally high risk of complications, hospitalization, and death 1, 2, 3
All hospitalized patients with suspected influenza, regardless of age, vaccination status, or time since symptom onset 1, 2, 4
Severely ill or progressively worsening patients at any point in their illness course 1, 2, 4
Immunocompromised patients (including those on long-term corticosteroids, chemotherapy, HIV, transplant recipients) should receive treatment even beyond 48 hours 1, 4
Pregnant women (any trimester) and women within 2 weeks postpartum 4
Adults ≥65 years due to increased mortality risk 1, 4

High-Risk Conditions Warranting Treatment

Chronic pulmonary disease (asthma, COPD, cystic fibrosis, bronchiectasis) 1, 4
Chronic cardiac disease (excluding isolated hypertension) 1, 4
Chronic renal disease, chronic liver disease, diabetes mellitus 1, 4
Neurologic or neurodevelopmental disorders 1, 2
Morbid obesity (BMI ≥40) 2
Residents of nursing homes or chronic-care facilities 1, 4

Consider Treatment For

Otherwise healthy children and adults with suspected influenza when treatment can be initiated within 48 hours of symptom onset 1, 2
Patients whose household contacts are <6 months old (cannot be vaccinated) or have high-risk conditions 1, 2

Dosing Regimens

Adults and Adolescents ≥13 Years

75 mg orally twice daily for 5 days 1, 2, 4
Administer with or without food; taking with meals reduces nausea 1, 5

Pediatric Dosing (Children ≥12 Months)

Body Weight	Dose (Twice Daily for 5 Days)
≤15 kg	30 mg (5 mL of 6 mg/mL suspension)
>15–23 kg	45 mg (7.5 mL)
>23–40 kg	60 mg (10 mL)
>40 kg	75 mg (12.5 mL or one 75 mg capsule)

1, 2, 3

Infants <12 Months

Term infants 0–8 months: 3 mg/kg per dose twice daily 1, 2, 3
Infants 9–11 months: 3.5 mg/kg per dose twice daily 1, 2, 3
Preterm infants: Dose adjusted by postmenstrual age:
- <38 weeks: 1.0 mg/kg twice daily
- 38–40 weeks: 1.5 mg/kg twice daily
- 40 weeks: 3.0 mg/kg twice daily 1, 2

Renal Impairment Dosing

Creatinine Clearance	Treatment Dose	Prophylaxis Dose
>30–60 mL/min	30 mg twice daily	30 mg once daily
10–30 mL/min	30 mg once daily or 75 mg once daily	30 mg every other day
ESRD on hemodialysis	30 mg after each dialysis session	30 mg after alternate sessions

1, 4

Timing: The 48-Hour Rule and Critical Exceptions

Optimal Window

Greatest benefit occurs when treatment starts within 48 hours of symptom onset, reducing illness duration by 1–1.5 days (approximately 26–36 hours) 1, 2, 6, 7
Earlier is better: Treatment within 12 hours reduces illness duration by an additional 74.6 hours compared to treatment at 48 hours; within 24 hours by an additional 53.9 hours 6

Treatment Beyond 48 Hours: When to Proceed

Do NOT withhold oseltamivir beyond 48 hours in:

Hospitalized patients with severe or progressive illness—mortality benefit persists when initiated up to 96 hours after symptom onset (OR 0.21 for death within 15 days) 2, 4, 8
All high-risk patients listed above, particularly immunocompromised, elderly, or those unable to mount adequate febrile response 1, 2, 4
Children <2 years remain high-risk and benefit from treatment even when started late 1, 2, 3
Patients with influenza pneumonia or suspected secondary bacterial complications 1

Do NOT start treatment beyond 48 hours in:

Otherwise healthy outpatients (no chronic conditions, not deteriorating) who present >48 hours after symptom onset—supportive care alone is appropriate 2

Alternative Antivirals

Zanamivir (Inhaled)

10 mg (two 5-mg inhalations) twice daily for 5 days 1, 2
Approved for children ≥7 years (treatment) or ≥5 years (prophylaxis) 1, 2
Contraindicated in patients with chronic respiratory disease (asthma, COPD) due to bronchospasm risk 1, 2, 4
More difficult to administer than oseltamivir 1, 2

Peramivir (IV)

One 600-mg IV infusion over 15–30 minutes (single dose) 1
Approved for children ≥2 years with acute uncomplicated influenza ≤2 days of symptom onset 1, 2
Not recommended for prophylaxis 1, 2

Baloxavir

Approved for patients ≥12 years: 40 mg (40–80 kg) or 80 mg (>80 kg) as a single oral dose 1
Emerging resistance reported, particularly in Japan 2

Amantadine and Rimantadine

Do NOT use—high levels of resistance (>99%) persist among circulating influenza strains 1, 2

Expected Clinical Benefits

Reduces illness duration by 1–1.5 days (17.6–36 hours) when started within 48 hours 1, 2, 6, 7
Reduces acute otitis media risk by 34–44% in children 1, 2, 4
Reduces pneumonia risk by 50% 2, 4
Reduces hospitalization risk in outpatients 4
Reduces mortality in hospitalized and high-risk patients (OR 0.21 for death within 15 days) 2, 4
Reduces secondary complications requiring antibiotics by 35% 2
Reduces viral shedding duration and quantity 6, 5

Safety and Adverse Effects

Vomiting is the most common adverse effect, occurring in 5–15% of treated patients (vs 9% with placebo); usually mild and transient 1, 2, 3, 6, 5
Nausea occurs in approximately 10% of patients; reduced when taken with food 6, 5, 7
Diarrhea may occur in children <1 year 1, 2, 3
No established link between oseltamivir and neuropsychiatric events despite early concerns—extensive surveillance has failed to establish causation 1, 2, 3

Critical Clinical Pitfalls to Avoid

Do NOT Wait for Laboratory Confirmation

Initiate treatment immediately based on clinical suspicion during influenza season (acute fever, cough, myalgia, local influenza activity) 1, 2, 4, 3
Rapid antigen tests have low sensitivity (especially for H1N1) and should never be used to rule out influenza or delay treatment 1, 2
RT-PCR is the gold standard but takes hours—do not delay treatment while awaiting results 2

Do NOT Withhold Treatment Based on Vaccination Status

Oseltamivir should be given to symptomatic patients regardless of vaccination status, as vaccine effectiveness varies by season and strain match 1, 2

Do NOT Use Prophylaxis Dosing for Treatment

Prophylaxis is once daily; treatment is twice daily 1, 2
If a patient on prophylaxis becomes symptomatic, switch immediately to full treatment dosing (twice daily) without waiting for test results 2

Do NOT Routinely Add Antibiotics

Antibiotics are not indicated for uncomplicated influenza 2, 4
Add antibiotics only if there is clear evidence of secondary bacterial infection (persistent high fever >4–5 days, new consolidation on imaging, purulent sputum, clinical deterioration despite oseltamivir) 1, 2
First-line antibiotics for secondary bacterial pneumonia: co-amoxiclav or cefuroxime/cefotaxime PLUS macrolide (clarithromycin/azithromycin) 1

Post-Exposure Prophylaxis

Indications

High-risk household contacts (infants <6 months, elderly, immunocompromised) exposed within 48 hours 1, 2
Unvaccinated healthcare workers caring for high-risk patients during outbreaks 2
Institutional outbreak control in nursing homes—all eligible residents receive prophylaxis for ≥2 weeks or until 1 week after outbreak ends 2
Severely immunocompromised patients for whom vaccination is contraindicated or ineffective 2

Dosing

Adults and adolescents ≥13 years: 75 mg once daily for 10 days 1, 2
Children ≥12 months: Same weight-based doses as treatment, but once daily for 10 days 1, 2
Infants 3–8 months: 3 mg/kg once daily 1, 2
Infants 9–11 months: 3.5 mg/kg once daily 1, 2
Not recommended for infants <3 months unless situation is judged critical 2

Timing

Must be started within 48 hours of exposure for optimal effectiveness 2
If >48 hours have elapsed, do not initiate prophylaxis—instead, educate caregivers to monitor closely and begin full-dose treatment promptly if symptoms appear 2

Important Caveats

Prophylaxis does not replace vaccination—influenza vaccine should be offered whenever not contraindicated 2
Live-attenuated influenza vaccine (LAIV) should not be given within 2 weeks before or 48 hours after oseltamivir; use inactivated vaccine (IIV) instead 2, 4

Resistance Monitoring

>99% of circulating influenza A(H1N1)pdm09, A(H3N2), and B viruses remain susceptible to oseltamivir, peramivir, and zanamivir 2
Resistance rates for neuraminidase inhibitors are <0.5% for most strains 2
Ongoing surveillance conducted by CDC 2

Special Populations

Pregnant Women

Oseltamivir is safe and recommended during pregnancy—benefits outweigh risks 2, 4
Standard adult dosing: 75 mg twice daily for 5 days 4

Elderly (≥65 Years)

High-dose, recombinant, or adjuvanted influenza vaccine preferred for superior immunogenicity 4
Standard oseltamivir dosing unless renal impairment present 4

Patients with Chronic Cardiac or Respiratory Disease

Oseltamivir is preferred over zanamivir due to bronchospasm risk with inhaled zanamivir 4
Treatment should not be withheld beyond 48 hours in these high-risk patients 2, 4

Formulation and Administration

Oral suspension (6 mg/mL) is the preferred formulation for infants and young children who cannot swallow capsules 1, 2, 3
Capsules available in 30 mg, 45 mg, and 75 mg strengths 1
If commercial suspension is unavailable, pharmacies can compound from capsules to achieve 6 mg/mL concentration 1, 2, 3
Administer with or without food; taking with meals reduces gastrointestinal side effects 1, 6, 5

Key Takeaway Algorithm

Clinical Scenario	Action
Child <2 years OR hospitalized OR high-risk with influenza-like illness during flu season	Start oseltamivir immediately; do not wait for lab confirmation
Otherwise healthy patient presenting ≤48 hours after symptom onset	Strongly consider oseltamivir to shorten illness and reduce complications
High-risk patient presenting >48 hours but deteriorating or severely ill	Continue or initiate oseltamivir despite delayed presentation
Otherwise healthy outpatient presenting >48 hours, not deteriorating	Supportive care only; do not start oseltamivir
Household contact of confirmed case (high-risk or <6 months)	Prophylaxis: once-daily oseltamivir for 10 days if within 48 hours of exposure

1, 2, 4, 3

What antiviral regimen should be initiated for a generally healthy adult or child older than one year with influenza, including dosing, timing, and alternatives for high‑risk or severely ill patients?

Help us tailor your experience